MK-677 vs GHRP-2 — Non-Peptide Oral vs Peptide Injectable Ghrelin-Receptor Agonists

Mechanism side-by-side

Both compounds activate the same receptor — GHS-R1a, the ghrelin receptor. Both amplify pulsatile GH release rather than driving a sustained non-pulsatile GH signal (which is what exogenous recombinant GH produces). The difference between them is chemistry, not pharmacology at the receptor.

MK-677 is a small-molecule piperidine derivative — a non-peptide organic compound designed to bind GHS-R1a in a way that mimics ghrelin's activating conformation. Its oral bioavailability and 4-6 hour half-life make daily oral dosing practical, which is unusual for a compound targeting a peptide-hormone receptor: most ghrelin-receptor ligands are themselves peptides with the oral-bioavailability problems that peptides typically carry. That property was what motivated Merck's development programme in the 1990s — GH-deficiency and osteoporosis indications wanted a once-daily oral option rather than an injectable one, and MK-677's chemistry made that feasible.

GHRP-2 is a synthetic hexapeptide — six amino acids, structurally unrelated to MK-677's small-molecule scaffold, but converging on the same receptor. Poor oral bioavailability (typical of peptides, which are broken down by gastrointestinal proteases before absorption) and a short (~30-45 minute) plasma half-life meant that, in clinical research, GHRP-2 required multi-daily subcutaneous or intranasal dosing to sustain a GH-secretion signal. In Japan, pralmorelin reached limited licensed use as a diagnostic agent (KP-102, "Kaken 102") for the standard GH-deficiency stimulation test — a single-dose diagnostic use in which a clinician administers the peptide once and measures the resulting GH pulse, not a chronic therapy administered repeatedly over weeks or months.

The pharmacokinetic gap between the two compounds — hours versus tens of minutes — is the single largest practical difference in how each has been used in published research. A long-half-life oral agent supports sustained, chronic dosing studies; a short-half-life injectable peptide supports acute, single-timepoint diagnostic use or intensive multi-daily dosing protocols. That gap, more than any difference in receptor pharmacology, explains why the two compounds ended up in such different research and regulatory lanes.

Evidence base — head-to-head vs single-arm

No published trial has tested MK-677 and GHRP-2 head-to-head in the same study population. Neither compound has a modern outcomes-trial evidence base — both peaked in clinical research in the late 1990s to early 2000s, and the comparison below draws on each compound's separate literature rather than a shared trial.

MK-677 landmark trials: Chapman 1996 (PMID 8954023, GH/IGF-1 axis stimulation in elderly), Murphy 1998 (catabolism reversal), Murphy 1999 (PMID 10404019, bone-turnover markers), Murphy 2001 (osteoporosis — negative on BMD). Chapman 1996 specifically found that daily oral MK-677 sustained IGF-1 levels in the range typically seen in younger adults, a durable elevation rather than a transient pulse. Murphy 1999 extended that work by showing increases in biochemical markers of bone turnover in both healthy and functionally impaired elderly adults, which was the mechanistic basis for testing MK-677 in osteoporosis. The negative BMD result in the follow-on osteoporosis trial contributed to Merck discontinuing the programme — a case where a positive biomarker signal (bone turnover markers) did not translate into the harder clinical endpoint (measured bone mineral density).

GHRP-2 evidence: primarily pharmacology and pharmacokinetic studies, summarised in the Furuta 2004 Drugs in R&D overview (PMID 15230633), plus the Japanese diagnostic-agent development pathway. No modern outcomes trials exist for GHRP-2 in the reference list this page relies on.

The Sigalos & Pastuszak 2018 review (PMID 28400207) covers growth hormone secretagogues as a class, including both small-molecule and peptide agents, and is a useful cross-compound reference for how the safety and efficacy literature for this drug class has been synthesised more recently than the individual 1990s-era trials.

Clinical use cases

Neither compound has reached a general clinical indication. MK-677's closest approach to a licensed use was the osteoporosis programme, which stopped after the negative BMD trial; it has no approved indication today, and Merck's development was discontinued rather than transferred to another sponsor. GHRP-2's only regulatory foothold anywhere is the Japanese diagnostic use as a GH-stimulation test agent (KP-102) — a narrow, single-dose clinical-testing context, not a therapeutic indication. Outside of that Japanese diagnostic pathway, GHRP-2's research use has been in mechanism and pharmacology studies rather than any use case with a defined patient population.

For a UK-based researcher, this means neither compound offers a route into an established clinical protocol. The practical distinction is between reading MK-677's literature as a case study in why a positive biomarker trial (bone turnover markers, Murphy 1999) did not guarantee a positive hard-endpoint trial (BMD), versus reading GHRP-2's literature as a case study in how a peptide secretagogue found a narrow, single-country diagnostic niche rather than broad therapeutic development. Both are instructive for understanding how GH-secretagogue-class compounds have actually been used in formal research and clinical-testing settings, as distinct from how they are marketed in grey-market research-chemical contexts.

Safety signals compared

The published safety data for the two compounds sits at different depths. MK-677's safety data comes primarily from the Chapman 1996 and Murphy 1999 trials in elderly cohorts, plus the broader secretagogue-class review in Sigalos & Pastuszak 2018 — which notes GH-secretagogue-class effects including fluid retention, insulin sensitivity changes, and the general caveats that apply to sustained GH/IGF-1 elevation. GHRP-2's safety literature is thinner in the reference list this page draws on, being largely pharmacology-focused (Furuta 2004) rather than built around sustained-dosing safety trials, reflecting its typical single-dose or short-course diagnostic use rather than a chronic-administration research history. Neither compound's cited literature supports a definitive comparative safety ranking; the depth difference reflects how each compound was actually studied (chronic dosing for MK-677, largely acute/diagnostic dosing for GHRP-2) rather than necessarily reflecting different underlying risk.

UK regulatory context

Neither is a licensed medicine in the UK. Both are on the WADA prohibited list (S2.2 category — GH secretagogues), and both are sold as "research chemicals" via online supplement / grey-market channels, none of which have regulatory sanction for human use. Neither compound's development reached the stage of a UK or EU marketing authorisation application, in contrast to some other peptide classes covered on this site that have reached formal regulatory review.

Advertising either compound for human use in the UK falls under MHRA rules for unlicensed-medicine advertising — see the POM advertising hub. WADA-prohibited status is a separate, sport-specific regulatory framework from MHRA licensing — see Peptides and sports anti-doping for how the two frameworks relate.

Verdict / Which to choose (or neither)

Neither compound is a UK medicine, and neither has an evidence base that supports a general clinical-use recommendation. Where the two diverge is in what their respective published literatures actually demonstrate. MK-677's chronic-dosing trials (Chapman 1996, Murphy 1999) are the more directly relevant reading for a researcher interested in sustained GH/IGF-1 axis elevation over weeks to months in an oral-dosing context. GHRP-2's literature (Furuta 2004) is the more directly relevant reading for a researcher interested in the acute, single-pulse GH-secretion response used diagnostically in Japan, or in pralmorelin's specific receptor pharmacology as a comparator peptide. The oral-versus-injectable and chronic-versus-acute distinctions are the practical basis for choosing which literature to read — not any claim that one compound is closer to approval or safer than the other, since neither has reached general licensing anywhere and the Sigalos 2018 class review does not rank individual secretagogues by safety.

Related pages

• MK-677 monograph
• GHRP-2 monograph
• Ipamorelin monograph — selective peptide GHS comparator
• GH axis mechanism map
• Peptides and sports anti-doping

Verdict — research-question matching

Same receptor target, but effectively different tools. MK-677's oral bioavailability and once-daily dosing made it a viable candidate for chronic indications like osteoporosis; when the osteoporosis programme did not produce a licensable BMD gain, its development stopped. GHRP-2 is a research peptide that reached limited licensed use only as a GH-deficiency diagnostic (Japan). Neither is a UK medicine. Both are WADA-prohibited. A UK reader looking at either compound is looking at published mechanism and PK research on an unapproved product — not at anything with a UK regulatory pathway.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

1. Chapman IM, Bach MA, et al.. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. 1996;81(12) :4249-4257 · PMID: 8954023
2. Murphy MG, Bach MA, et al. (MK-677 Study Group). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research. 1999;14(7) :1182-1188 · PMID: 10404019
3. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. 2018;6(1) :45-53 · PMID: 28400207
4. n/a. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102 D-LN. Drugs in R&D. 2004;5(4) :236-239 · PMID: 15230633